Poland· PL-100529750
Imaavy
A immunosuppressants product containing nipokalimab, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nipokalimab is registered in 3 of 19 countries.
Countries holding a registration under ATC L04A (immunosuppressants), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Nipokalimab · ATC L04A
3 / 19 countries
- Icelandprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Nipokalimab
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L04A
- ATC class
- IMMUNOSUPPRESSANTS
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05413868126808
- gtin04150197526367
- gtin05413868126792
- gtin04150197526138
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nipokalimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesIMAAVYJanssen Biotech, Inc.
- CzechiaIMAAVYJanssen-Cilag International N.V., Beerse
- BelgiumImaavy 185 mg/mlJanssen-Cilag International
- SwedenImaavy 185 mg/ml Koncentrat till infusionsvätska, lösningJanssen-Cilag International NV
- IrelandImaavy 185 mg/mL concentrate for solution for infusionJanssen-Cilag International NV
- FinlandImaavyJanssen Cilag International
- IcelandIMAAVYJanssen Cilag International
- SwitzerlandImaavy 1200 mg/6.5 ml (185 mg/ml), Konzentrat zur Herstellung einer InfusionslösungJanssen-Cilag AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imaavy
- Liechtenstein · Imaavy
- Norway · Imaavy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1fecf8d6-ae4b-4ebe-8a2e-f4b99329fba4 GET /v1/drugs/1fecf8d6-ae4b-4ebe-8a2e-f4b99329fba4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "185 mg/ml",
"packaging": "05413868126808 ¦ Rpz ¦ EU/1/25/1989/001 ¦ 164974\n1 fiol. 1,62 ml\n¦ UR/Z/4c/025/26 - 04150197526367\n05413868126792 ¦ Rpz ¦ EU/1/25/1989/002 ¦ 164975\n1 fiol. 6,5 ml\n¦ UR/Z/4c/305/25 - 04150197526138",
"substance": "Nipokalimab 185 mg/ml",
"common_name": "Nipokalimab",
"pl_product_id": "100529750",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nipokalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.